A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
NCT00245362
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Pancreatic Cancer
Nonresectable Pancreatic Cancer
Interventions
BIOLOGICAL:
CG 8020 and CG 2505
Sponsor
Cell Genesys